SSShashank Kumar Singh

Shashank Kumar Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shashank Kumar Singh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Arem Qayum

    Cancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR), Canal Road, Jammu 180001, India

    2 shared publications
  • Asmita Magotra

    PK-PD, Toxicology and Formulation Division, Indian Institute of Integrative Medicine, CSIR, Jammu 180001, India

    2 shared publications
  • Syed Mohmad Shah

    Sher-e-Kashmir University of Agricultural Sciences & Technology of Kashmir, Srinagar 190001, India

    2 shared publications
  • Utpal Nandi

    PK-PD, Toxicology and Formulation Division, Indian Institute of Integrative Medicine, CSIR, Jammu 180001, India

    2 shared publications
  • Arvind Kumar

    Natural Product Microbes Division, Indian Institute of Integrative Medicine, CSIR, Jammu 180001, India

    1 shared publication
  • Bhahwal Ali Shah

    Natural Product Microbes Division, Indian Institute of Integrative Medicine, CSIR, Jammu, 180001, India

    1 shared publication

Latest Publications

  • 2-Pyridin-4-yl-methylene-beta-boswellic Acid─A Potential Candidate for Targeting O6-Methylguanine-DNA Methyltransferase Epi-transcriptional Reprogramming in KRAS G13D─Microsatellite Stable, G12V─Microsatellite Instable Mutant Colon Cancer

    by Arem Qayum, Jasvinder Singh, Arvind Kumar, Syed Mohmad Shah, Shubham Srivastava, Manoj Kushwaha, Asmita Magotra, Utpal Nandi, Ruchi Malik, Bhahwal Ali Shah, et al.

    PMBA (2-Pyridin-4-yl-methylene-beta-boswellic acid), screened from among the 21 novel series of semisynthetic analogues of β-boswellic acid, is being presented as a lead compound for integrative management of KRAS mutant colorectal cancer (CRC), upon testing and analysis for its anticancerous activity on a panel of NCI-60 cancer cell lines and in vivo models of the disease. PMBA (1.7-29 μM) exhibited potent proliferation inhibition on the cell lines and showed sensitivity in microsatellite instability and microsatellite stable (GSE39582 and GSE92921) subsets of KRAS gene (Kirsten rat sarcoma viral oncogene homolog)-mutated colon cell lines, as revealed via flow cytometry analysis. A considerable decrease in mitogen-activated protein kinase pathway downstream effectors was observed in the treated cell lines via the western blot and STRING (Search tool for the retrieval of interacting genes/proteins) analysis. PMBA was further found to target KRAS at its guanosine diphosphate site. Treatment of the cell lines with PMBA showed significant reduction in MGMT promoter methylation but restored MGMT (O6-methylguanine-DNA methyltransferase) messenger ribonucleic acid expression via significant demethylation of the hypermethylated CpG (Cytosine phosphate guanine) sites in the MGMT promoter. A significant decrease in dimethylated H3K9 (Dimethylation of lysine 9 on histone 3) levels in the MGMT promoter in DNA hypo- and hypermethylated HCT-116G13D and SW-620G12V cells was observed after treatment. In the MNU (N-methyl-N-nitrosourea)-induced CRC in vivo model, PMBA instillation restricted and repressed polyp formation, suppressed tumor proliferation marker Ki67 (Marker of proliferation), ablated KRAS-associated cytokine signaling, and decreased mortality. Clinical trial data for the parent molecule revealed its effectiveness against the disease, oral bioavailability, and system tolerance. Comprehensively, PMBA represents a new class of KRAS inhibitors having a therapeutic window in the scope of a drug candidate. The findings suggest that the PMBA analogue could inhibit the growth of human CRC in vivo through downregulation of cancer-associated biomarkers as well as reactivate expression of the MGMT gene associated with increased H3K9 acetylation and H3K4 methylation with facilitated transcriptional activation, which might be important in silencing of genes associated with upregulation in the activity of KRAS.


  • Open Access

    Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells

    by Arem Qayum, Asmita Magotra, Syed Mohmad Shah, Utpal Nandi, P.R. Sharma, Bhahwal Ali Shah, Shashank Kumar Singh